Dr. Stelios B. Papadopoulos is Chairman at Biogen, Inc., Chairman at Regulus Therapeutics, Inc., Chairman & Treasurer at Fondation Santé, Chairman at Exelixis, Inc. and Strategic Advisor at Symphony Capital LLC.
He is on the Board of Directors at Biogen Idec, Inc. (North Carolina), BG Medicine, Inc., Diacrin, Inc., Joule Unlimited Technologies, Inc. and National Marrow Donor Program. Dr. Papadopoulos was previously employed as Chief Executive Officer by Merck KGaA, Founder by Cellzome Ltd., Vice Chairman by Cowen & Co. LLC, Chairman by PaineWebber Development Corp., Chief Executive Officer by CN Biosciences, Inc., Chairman by Anadys Pharmaceuticals, Inc., President by Fisher Scientific International, Inc., President by Instrumentation Laboratory Co., Investment Banker by PaineWebber, Inc., and Vice President-Equity Research Department by Drexel Burnham Lambert, Inc.
He also served on the board at GenVec, Inc., US Pathology Labs, Inc., SGX Pharmaceuticals, Inc., Ngen, Inc., Biogen Idec New Ventures, Inc., Cellzome, Inc. and Neuronyx, Inc.
He received his undergraduate degree from Northrop University, a graduate degree from New York University, an MBA from New York University and a doctorate degree from New York University.